Momenta Pharmaceuticals, Inc. (MNTA)

[indigokid]

The target price change seems overly dramatic given market share value of Copaxone has stayed about the same including recent price increase.

The shift to 3x weekly while dramatic may not hold very well with a generic at a 20-30% discount and no increase in efficacy. Insurance payors will likely mandate lower cost generic over 3x convenience.

Now that we are in 2015 seems like the patent expiry is more important than any legal case.

Maybe this firm is the broker for the shorts???